uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
High Functional CD70 Expression on alpha-Type 1-Polarized Dendritic Cells from Patients with Chronic Lymphocytic Leukaemia
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology.
Show others and affiliations
2014 (English)In: Scandinavian Journal of Immunology, ISSN 0300-9475, E-ISSN 1365-3083, Vol. 79, no 6, 415-422 p.Article in journal (Refereed) Published
Abstract [en]

Antigen-loaded dendritic cells (DCs) used as anticancer vaccine holds promise for therapy, but needs to be optimized. The most frequently described DC vaccine is being matured with a cocktail containing prostaglandin E2 (PGE2DC). However, even though PGE2DCs express both costimulatory and migratory receptors, their IL-12p70-prodcution is low, leading to an insufficient Th1 immune response. As an alternative, -type-1 polarized DCs (DC1s) have shown a superior production of IL-12p70 and subsequent activation of effector cells. From chronic lymphocytic leukaemia (CLL) patients, DC1s can be generated to induce a functional Th1-immune response. Yet, another costimulatory receptor, CD70, appears to be essential for optimal DC function by promotion of T cell survival and function. So far, PGE2 is suggested as one of the most important factors for the induction of CD70 expression on DCs. Therefore, we wanted to investigate whether DC1s have the ability to express functional CD70. We found that CD70 expression on DC1s could be upregulated in the same manner as PGE2DCs. In an allogeneic mixed leucocyte reaction, we found that antibody-blocking of CD70 on DC1s from controls reduced effector cell proliferation although this could not be found when using CLL DC1s. Nevertheless, CD70-blocking of DC1s from both controls and patients with CLL had a negative influence on the production of both IL-12p70 and the Th1 cytokine IFN-, while the production of the Th2 cytokine IL-5 was enhanced. Together, this study further suggests that DC1s should be considered as a suitable candidate for clinical antitumour vaccine strategies in patients with CLL.

Place, publisher, year, edition, pages
2014. Vol. 79, no 6, 415-422 p.
National Category
Immunology in the medical area
URN: urn:nbn:se:uu:diva-228725DOI: 10.1111/sji.12172ISI: 000337588500009OAI: oai:DiVA.org:uu-228725DiVA: diva2:734771
Available from: 2014-07-21 Created: 2014-07-21 Last updated: 2014-07-21Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Karlsson-Parra, Alex
By organisation
Clinical Immunology
In the same journal
Scandinavian Journal of Immunology
Immunology in the medical area

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 192 hits
ReferencesLink to record
Permanent link

Direct link